Cserr HF, Cooper DN, Suri PK, Patlak CS: Efflux of radiolabeled polyethylene glycols and albumin from rat brain. AmJ Physiol 1981,240(4):F319-F28.
CAS
Google Scholar
Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, et al.: Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. NeuropatholApplNeurobiol 2008,34(2):131–44.
CAS
Google Scholar
Weller RO, Boche D, Nicoll JA: Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta neuropathologica 2009,118(1):87–102. 10.1007/s00401-009-0498-z
Article
CAS
PubMed
Google Scholar
Attems J: Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol(Berl) 2005,110(4):345–59. 10.1007/s00401-005-1074-9
Article
CAS
Google Scholar
Attems J, Jellinger K, Thal DR, Van Nostrand W: Review: sporadic cerebral amyloid angiopathy. Neuropathology and applied neurobiology 2011,37(1):75–93. Epub 2010/10/16 10.1111/j.1365-2990.2010.01137.x
Article
CAS
PubMed
Google Scholar
Kawai M, Kalaria RN, Cras P, Siedlak SL, Velasco ME, Shelton ER, et al.: Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain research. 1993, 623: 142–6. 10.1016/0006-8993(93)90021-E
Article
CAS
PubMed
Google Scholar
Frackowiak J, Zoltowska A, Wisniewski HM: Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. J Neuropathol Exp Neurol 1994,53(6):637–45. 10.1097/00005072-199411000-00011
Article
CAS
PubMed
Google Scholar
Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO: Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. NeuropatholAppl Neurobiol 2003,29(2):106–17. 10.1046/j.1365-2990.2003.00424.x
Article
CAS
Google Scholar
McCarron MO, Nicoll JA: Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage 6. Lancet Neurol 2004,3(8):484–92. 10.1016/S1474-4422(04)00825-7
Article
PubMed
Google Scholar
Werring DJ, Sperling R: Inflammatory cerebral amyloid angiopathyand amyloid-modifying therapies: Variations on the same ARIA? Annals of neurology 2013. Epub 2013/03/26
Google Scholar
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al.: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. AmJ Pathol 1999,155(3):853–62. 10.1016/S0002-9440(10)65184-X
Article
CAS
Google Scholar
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al.: Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010,330(6012):1774. Epub 2010/12/15 10.1126/science.1197623
Article
PubMed Central
CAS
PubMed
Google Scholar
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999,400(6740):173–7. 10.1038/22124
Article
CAS
PubMed
Google Scholar
Cribbs DH, Agadjanyan MG: Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II. CNS & neurological disorders drug targets 2009,8(2):82–7. 10.2174/187152709787847270
Article
CAS
Google Scholar
Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. NatMed 2003,9(4):448–52.
CAS
Google Scholar
Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease 49. Brain Pathol 2004,14(1):11–20.
Article
CAS
PubMed
Google Scholar
Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al.: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005,64(1):129–31. 10.1212/01.WNL.0000148590.39911.DF
Article
CAS
PubMed
Google Scholar
Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al.: Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain: a journal of neurology 2008,131(Pt 12):3299–310.
Article
CAS
Google Scholar
Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al.: Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet neurology 2012,11(3):241–9. Epub 2012/02/07 10.1016/S1474-4422(12)70015-7
Article
PubMed Central
CAS
PubMed
Google Scholar
Teeling JL, Carare RO, Glennie MJ, Perry VH: Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction. Acta neuropathologica 2012,124(4):479–90. 10.1007/s00401-012-0995-3
Article
PubMed Central
CAS
PubMed
Google Scholar
McCarron MO, Nicoll JA: Recurrent hemorrhage in cerebral amyloid angiopathy 68. Neurology 1998,51(3):924–5.
Article
CAS
PubMed
Google Scholar
Sjoberg AP, Trouw LA, Blom AM: Complement activation and inhibition: a delicate balance. Trends Immunol 2009,30(2):83–90. 10.1016/j.it.2008.11.003
Article
CAS
PubMed
Google Scholar
Kida S, Steart PV, Zhang ET, Weller RO: Perivascular cells act as scavengers in the cerebral perivascular spaces and remain distinct from pericytes, microglia and macrophages. Acta Neuropathol(Berl) 1993,85(6):646–52. 10.1007/BF00334675
Article
CAS
Google Scholar
Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al.: Abeta species removal after abeta42 immunization. JNeuropatholExpNeurol 2006,65(11):1040–8.
CAS
Google Scholar
Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN: Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 2007,144(3):950–60. 10.1016/j.neuroscience.2006.10.020
Article
PubMed Central
CAS
PubMed
Google Scholar
Fan R, Defilippis K, Van Nostrand WE: Induction of complement proteins in a mouse model of cerebral microvascular Abeta deposition. JNeuroinflammation 2007,4(1):22. 10.1186/1742-2094-4-22
Article
Google Scholar
Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, et al.: Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 2007,27(46):12721–31. 10.1523/JNEUROSCI.3201-07.2007
Article
CAS
Google Scholar
Vasilevko V, Xu F, Previti ML, Van Nostrand WE, Cribbs DH: Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J Neurosci 2007,27(49):13376–83. 10.1523/JNEUROSCI.2788-07.2007
Article
CAS
PubMed
Google Scholar
Head E, Barrett EG, Murphy MP, Das P, Nistor M, Sarsoza F, et al.: Immunization with fibrillar Abeta(1–42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine 2006,24(15):2824–34. 10.1016/j.vaccine.2005.12.058
Article
CAS
PubMed
Google Scholar
Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al.: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003,15(4):505–14. 10.1093/intimm/dxg049
Article
PubMed Central
CAS
PubMed
Google Scholar
Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D: Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 2004,15(1):11–20. 10.1016/j.nbd.2003.09.015
Article
CAS
PubMed
Google Scholar
Deane R, Bell RD, Sagare A, Zlokovic BV: Clearance of amyloid-beta peptide across the blood–brain barrier: implication for therapies in Alzheimer's disease. CNS & neurological disorders drug targets 2009,8(1):16–30. 10.2174/187152709787601867
Article
CAS
Google Scholar
Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, et al.: Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimer's & dementia: the journal of the Alzheimer's Association 2011,7(4):396–401. Epub 2011/07/26 10.1016/j.jalz.2011.05.2353
Article
CAS
Google Scholar
Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D, et al.: Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. EurJNeurosci 2006,24(9):2530–42.
Google Scholar
Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, et al.: Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. The Journal of neuroscience: the official journal of the Society for Neuroscience 2013,33(11):4923–34. Epub 2013/03/15 10.1523/JNEUROSCI.4672-12.2013
Article
CAS
Google Scholar
Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al.: Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet neurology 2012,11(7):597–604. Epub 2012/06/09 10.1016/S1474-4422(12)70140-0
Article
CAS
PubMed
Google Scholar